According to the sources provided, Cosentyx has shown consistent efficacy in prolonged treatment for certain conditions.
Cosentyx is a biologic medication that contains the active ingredient secukinumab. It is primarily used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug works by targeting and inhibiting a specific protein called interleukin-17A (IL-17A), which plays a role in the inflammatory process associated with these conditions [1].
A study published in the Journal of the American Academy of Dermatology evaluated the long-term efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis. The study followed patients for up to 5 years and found that Cosentyx maintained its efficacy in reducing disease severity over the long term. The study also reported a sustained improvement in quality of life measures for the patients [2].
Another study published in the Journal of Dermatological Treatment assessed the efficacy and safety of Cosentyx in patients with moderate-to-severe psoriasis over a period of 3 years. The study found that Cosentyx demonstrated sustained efficacy in reducing disease severity, with a high proportion of patients achieving significant improvement in their symptoms. The study also reported a favorable safety profile for Cosentyx throughout the treatment period [3].
Furthermore, a review article published in the journal Drugs evaluated the long-term efficacy and safety of Cosentyx in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. The review analyzed data from multiple clinical trials and real-world studies. It concluded that Cosentyx showed sustained efficacy and a favorable safety profile in the long-term treatment of these conditions [4].
In summary, based on the provided sources, Cosentyx has demonstrated consistent efficacy in prolonged treatment for psoriasis, psoriatic arthritis, and ankylosing spondylitis. It has shown sustained improvement in disease severity and quality of life measures over several years of treatment. However, it is important to note that individual responses to treatment may vary, and it is always advisable to consult with a healthcare professional for personalized medical advice.
Sources:
[1] DrugPatentWatch. Cosentyx - Secukinumab. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] Griffiths, C. E., Reich, K., Lebwohl, M., et al. (2021). Long-term efficacy and safety of secukinumab in patients with moderate-to-severe plaque psoriasis: Final 5-year results from the SCULPTURE extension study. Journal of the American Academy of Dermatology, 84(1), 92-100. doi: 10.1016/j.jaad.2020.06.070
[3] Mrowietz, U., Leonardi, C., Girolomoni, G., et al. (2019). Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE Extension Study). Journal of Dermatological Treatment, 30(6), 577-584. doi: 10.1080/09546634.2018.1544497
[4] Reich, K., Burden, A